Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A pharmaceutical composition comprising a solid dispersion of an HIV protease inhibitor or a combination of HIV protease inhibitors in a water soluble carrier wherein said water soluble carrier is polyethylene glycol 8000 (PEG 8000) and wherein the HIV protease inhibitor or the combination of HIV protease inhibitors is in amorphous form in the dispersion.

2-4. (canceled)

5. (currently amended) The composition of ~~Claim 2~~ Claim 1 wherein said HIV protease inhibitor is selected from the group consisting of:

~~(2S,3S,5S) 5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir);~~

(2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir);

~~(2S, 3S, 5S) 2-(2,6Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(I-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane (ABT-378);~~

(2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl] amino-1,6-diphenylhexane (ABT-378);

~~N-(2(R)-hydroxy-1-(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(I-(4-(3-pyridyl methyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);~~

N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridyl methyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);

5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;

1-Naphthoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4- t-butylamide;

5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;

~~[1S-[1R-(R-),2S*]-N[1]-[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2quinolinylcarbonyl)amino]-butanediamide;~~

1S-[1R-(R-),2S*]-N[1]-[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide;

VX-478;

DMP-323;

DMP-450;

AG1343 (nelfinavir);

BMS 186,318;

SC-55389a;

BILA 1096 BS;

U-140690, and

combinations thereof.

6. (currently amended) The composition of ~~Claim 2~~ Claim 1 wherein said HIV protease inhibitor is (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)1,6-diphenyl-3-hydroxyhexane (ritonavir).

7. (currently amended) The composition of ~~Claim 2~~ Claim 1 wherein said HIV protease inhibitor is (2S,3S,5S)-2-(2,6Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(l-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

8. (currently amended) The composition of ~~Claim 2~~ Claim 1 wherein said HIV protease inhibitor is a combination of ~~(2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)~~

~~carbonyl)L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane~~ (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino) carbonyl)L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and ~~(2S,3S,5S)-2-(2,6Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(I-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]amino-1,6-diphenylhexane~~ (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]amino-1,6-diphenylhexane (ABT-378).

9. (currently amended) The composition of ~~Claim 2~~ Claim 1 wherein said solid dispersion is encapsulated in a hard gelatin capsule.

10. (currently amended) The composition of ~~Claim 2~~ Claim 1 wherein said solid dispersion is compressed into a tablet.

11. (original) The composition of Claim 1 further comprising an additive or a mixture of additives independently selected from the group consisting of pharmaceutically acceptable surfactants and antioxidants.

12-18. (canceled)

19. (original) A method of treating an HIV infection comprising administering an effective amount of a solid dispersion of Claim 1 to a mammal in need of such treatment.

20. (currently Amended) The method of Claim 19 wherein said HIV protease inhibitor is selected from the group consisting of ~~(2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane~~ (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and ~~(2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(I-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl]amino-1,6-diphenylhexane~~ (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-

3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

21. (currently amended) The method of Claim 19 wherein said HIV protease inhibitor is a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino) carbonyl)L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and ~~(2S,3S,5S)-2-(2,6Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane~~ (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6- diphenylhexane (ABT-378).

22-29. (canceled)

30 (new) A pharmaceutical composition comprising a solid dispersion, wherein said solid dispersion includes a dispersion of amorphous ritonavir and a water soluble carrier.

31. (new) The pharmaceutical composition of claim 30, wherein said water soluble carrier is polyethylene glycol (PEG).

32. (new) The pharmaceutical composition of claim 31, wherein said solid dispersion further comprises a dispersion of (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]amino-1,6-diphenylhexane (ABT-378).

33. (new) The pharmaceutical composition of claim 30, wherein said water soluble carrier is PEG 8000.

34. (new) The pharmaceutical composition of claim 30, wherein said solid dispersion further comprises a dispersion of (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methylbutanoyl]amino-1,6-diphenylhexane (ABT-378).

35. (new) The pharmaceutical composition of claim 30, further comprising a hard gelatin capsule which encapsulates said solid dispersion.

36. (new) The pharmaceutical composition of claim 30, wherein said solid dispersion is compressed into a tablet.

37. (new) A pharmaceutical composition comprising a solid dispersion which includes a dispersion of amorphous ritonavir in PEG.

38. (new) The pharmaceutical composition of claim 37, wherein said PEG is PEG 8000.